SHTG Digest — Tuesday June 9, 2026

SHTG Digest — Friday July 3, 2026

A quiet cycle overall — no top-tier journal papers on our core targets cleared the bar and no genuinely new industry news broke in the last five days, so this episode leans on two next-best-tier papers (an ANGPTL3-inhibitor phase 3 extension and a pediatric SHTG risk-prediction study) while the Arrowhead/Ionis/Alnylam news front stayed silent beyond what's already been covered.

SHTG Digest — Tuesday June 30, 2026

A quiet science week surfaces a novel APOC3 role in diabetic retinal angiogenesis and a diagnostic yield study for monogenic HTG, while the industry story remains Ionis' Tryngolza commercial launch into the 3.6-million-patient sHTG market following last week's FDA approval.

SHTG Digest — Friday June 26, 2026

The week's dominant story is the FDA's June 24 approval of Ionis' Tryngolza (olezarsen) as the first-ever treatment for severe hypertriglyceridemia with a pancreatitis risk reduction claim; on the science side, three next-best-tier papers examine plozasiran's pharmacology, ApoC3's biphasic role across the MASLD spectrum, and urinary ANGPTL3 as a novel biomarker for podocyte injury.

SHTG Digest — Tuesday June 23, 2026

A fresh meta-analysis of 14 APOC3-inhibitor trials confirms 80% reduction in acute pancreatitis risk alongside a compelling indirect head-to-head of olezarsen versus volanesorsen in FCS, while the most important industry event this cycle is the looming June 30 FDA decision on Tryngolza for severe hypertriglyceridemia.

SHTG Digest — Friday June 19, 2026

A quiet breaking-news cycle on paper, but the lipid field is coiled for impact — a landmark Ionis FDA decision on olezarsen for severe hypertriglyceridemia is 11 days out, and fresh science clarifies who among heterozygous FCS-gene carriers will need APOC3-targeted therapy; on the bench, a novel SPP2–LPL axis offers a new handle on triglyceride homeostasis.